KRAS and non-small cell lung carcinoma: Sotorasib, a RAS GTPase family inhibitor for the treatment of solid tumors with KRAS G12C mutations, received approval from the Food and Drug Administration (FDA) in 2021 for treating adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying such mutations and who have undergone one or more prior systemic therapies [1].